SCYNEXIS (NASDAQ:SCYX – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.01, FiscalAI reports.
SCYNEXIS Stock Down 14.1%
SCYX stock traded down $0.54 during midday trading on Thursday, reaching $3.30. The stock had a trading volume of 133,699 shares, compared to its average volume of 133,241. The business has a fifty day simple moving average of $4.48 and a two-hundred day simple moving average of $5.50. The firm has a market cap of $32.84 million, a price-to-earnings ratio of -1.58 and a beta of 1.15. SCYNEXIS has a twelve month low of $3.28 and a twelve month high of $9.12.
Wall Street Analyst Weigh In
A number of analysts have commented on the company. Brookline Capital Markets reiterated a “buy” rating on shares of SCYNEXIS in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SCYNEXIS in a research report on Thursday, October 22nd. Wall Street Zen upgraded shares of SCYNEXIS from a “strong sell” rating to a “hold” rating in a research note on Sunday, August 16th. Finally, Guggenheim reissued a “buy” rating and issued a $33.00 price target (up from $24.00) on shares of SCYNEXIS in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $33.00.
Check Out Our Latest Analysis on SCYX
About SCYNEXIS
SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.
SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.
Read More
- Five stocks we like better than SCYNEXIS
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
